{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:00:05Z","timestamp":1792789205905,"version":"4.5.0"},"reference-count":157,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH, NCI","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an \u201concometabolite\u201d, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting \u03b1-ketoglutarate (\u03b1-KG)\/Fe(II)-dependent dioxgenases (\u03b1-KGDDs). Recent studies have revealed that D-2-HG affects DNA\/histone methylation, hypoxia signaling, DNA repair, and redox homeostasis, which impacts the oncogenesis of IDH-mutated cancers. In this review, we will discuss the current understanding of D-2-HG in cancer biology, as well as the emerging opportunities in therapeutics in IDH-mutated glioma.<\/jats:p>","DOI":"10.3390\/cells10092345","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T02:41:07Z","timestamp":1631068867000},"page":"2345","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["D-2-Hydroxyglutarate in Glioma Biology"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-5416","authenticated-orcid":false,"given":"Fu-Ju","family":"Chou","sequence":"first","affiliation":[{"name":"Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-938X","authenticated-orcid":false,"given":"Fengchao","family":"Lang","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-0867","authenticated-orcid":false,"given":"Chunzhang","family":"Yang","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 1142E, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2016.04.025","article-title":"Oncometabolites: Unconventional triggers of oncogenic signalling cascades","volume":"100","author":"Sciacovelli","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","article-title":"Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas","volume":"27","author":"Sanson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1158\/1078-0432.CCR-09-0715","article-title":"IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas","volume":"15","author":"Nobusawa","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/0008-5472.CAN-20-3730","article-title":"Oncometabolites in Cancer: Current Understanding and Challenges","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-015-2048-y","article-title":"IDH mutation is associated with higher risk of malignant transformation in low-grade glioma","volume":"127","author":"Leu","year":"2016","journal-title":"J. Neuro-Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncb3124","article-title":"Metabolic pathways promoting cancer cell survival and growth","volume":"17","author":"Boroughs","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/10409238.2012.735643","article-title":"The role of phosphatidylcholine and choline metabolites to cell proliferation and survival","volume":"48","author":"Ridgway","year":"2013","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J. Gen. Physiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/BF01504608","article-title":"\u00dcber den stoffwechsel der carcinomzelle","volume":"12","author":"Warburg","year":"1924","journal-title":"Naturwissenschaften"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: How does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1373\/clinchem.2016.267666","article-title":"Oncometabolites: A new paradigm for oncology, metabolism, and the clinical laboratory","volume":"63","author":"Collins","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fonc.2012.00085","article-title":"The emerging role of fumarate as an oncometabolite","volume":"2","author":"Yang","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/prac.18681030124","article-title":"Ueber die glutans\u00e4ure, das zersetzungsproduct der glutamins\u00e4ure durch salpetrige s\u00e4ure","volume":"103","author":"Ritthausen","year":"1868","journal-title":"J. F\u00fcr Prakt. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF02312543","article-title":"L-2-Hydroxyglutaric aciduria: An inborn error of metabolism?","volume":"3","author":"Duran","year":"1980","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF02312516","article-title":"d-2-Hydroxyglutaric aciduria: Case report and biochemical studies","volume":"3","author":"Chalmers","year":"1980","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/427890","article-title":"Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause D-2-hydroxyglutaric aciduria","volume":"76","author":"Struys","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1126\/science.1192632","article-title":"IDH2 mutations in patients with D-2-hydroxyglutaric aciduria","volume":"330","author":"Kranendijk","year":"2010","journal-title":"Science"},{"key":"ref_23","first-page":"2122","article-title":"Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value","volume":"116","author":"Abbas","year":"2010","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-10-0473","article-title":"Identification of several novel non-p. R132 IDH1 variants in thyroid carcinomas","volume":"163","author":"Hemerly","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ng.994","article-title":"Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2","volume":"43","author":"Amary","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: A systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11060-012-0844-1","article-title":"IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas","volume":"108","author":"Juratli","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40610-020-00126-z","article-title":"Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?","volume":"6","author":"Cojocaru","year":"2020","journal-title":"Curr. Mol. Biol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1158\/0008-5472.CAN-09-2650","article-title":"Mutant metabolic enzymes are at the origin of gliomas","volume":"69","author":"Yan","year":"2009","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"eaaw4543","DOI":"10.1126\/sciadv.aaw4543","article-title":"Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease","volume":"5","author":"Murnan","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: A cancer hallmark even warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1038\/onc.2011.416","article-title":"Identification of additional IDH mutations associated with oncometabolite R (\u2212)-2-hydroxyglutarate production","volume":"31","author":"Ward","year":"2012","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2015.06.009","article-title":"2-Hydroxyglutarate inhibits ATP synthase and mTOR signaling","volume":"22","author":"Fu","year":"2015","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fasebj.2020.34.s1.03606","article-title":"Metabolic Regulation of Stem Cell Fate and Function","volume":"34","author":"Shapira","year":"2020","journal-title":"FASEB J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1373\/clinchem.2004.033399","article-title":"Measurement of urinary D-and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography\u2013tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride","volume":"50","author":"Struys","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1750-3639.2011.00506.x","article-title":"Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography\/mass spectrometry","volume":"22","author":"Sahm","year":"2012","journal-title":"Brain Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-3-030-51652-9_11","article-title":"Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate","volume":"Volume 1280","author":"Hu","year":"2021","journal-title":"Cancer Metabolomics. Advances in Experimental Medicine and Biology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1158\/1078-0432.CCR-15-2965","article-title":"Selective detection of the D-enantiomer of 2-hydroxyglutarate in the CSF of glioma patients with mutated isocitrate dehydrogenase","volume":"22","author":"Kalinina","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41467-018-03905-6","article-title":"Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate","volume":"9","author":"Andronesi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat. Med."},{"key":"ref_45","first-page":"20190026","article-title":"Magnetic resonance spectroscopic imaging in gliomas: Clinical diagnosis and radiotherapy planning","volume":"2","author":"Laino","year":"2020","journal-title":"BJR Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3171\/2016.10.JNS161793","article-title":"Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting","volume":"128","author":"Tietze","year":"2017","journal-title":"J. Neurosurg."},{"key":"ref_47","first-page":"215","article-title":"The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas","volume":"22","author":"Semmler","year":"2018","journal-title":"Contemp. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","article-title":"Altered cellular metabolism in gliomas\u2014An emerging landscape of actionable co-dependency targets","volume":"20","author":"Bi","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cell.2017.11.031","article-title":"R-2HG exhibits anti-tumor activity by targeting FTO\/m6A\/MYC\/CEBPA signaling","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41588-017-0001-z","article-title":"Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence","volume":"50","author":"Turcan","year":"2018","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/epi.14.80","article-title":"Genetic alterations of DNA methylation machinery in human diseases","volume":"7","author":"Hamidi","year":"2015","journal-title":"Epigenomics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.4161\/cc.8.11.8580","article-title":"Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids","volume":"8","author":"Iyer","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1126\/science.1210597","article-title":"Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine","volume":"333","author":"Ito","year":"2011","journal-title":"Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"a026518","DOI":"10.1101\/cshperspect.a026518","article-title":"TET2 in normal and malignant hematopoiesis","volume":"7","author":"Bowman","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrg.2017.33","article-title":"TET-mediated active DNA demethylation: Mechanism, function and beyond","volume":"18","author":"Wu","year":"2017","journal-title":"Nat. Rev. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.dnarep.2016.05.031","article-title":"TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis","volume":"43","author":"Mahfoudhi","year":"2016","journal-title":"DNA Repair"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"832","DOI":"10.7150\/jca.12010","article-title":"Genetic characterization of ten-eleven-translocation methylcytosine dioxygenase alterations in human glioma","volume":"6","author":"Kraus","year":"2015","journal-title":"J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11060-012-0914-4","article-title":"IDH1 mutations inhibit multiple \u03b1-ketoglutarate-dependent dioxygenase activities in astroglioma","volume":"109","author":"Liu","year":"2012","journal-title":"J. Neuro-Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/15592294.2019.1638701","article-title":"DNA hypermethylation in disease: Mechanisms and clinical relevance","volume":"14","author":"Ehrlich","year":"2019","journal-title":"Epigenetics"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1101\/gr.132738.111","article-title":"A heterozygous IDH1R132H\/WT mutation induces genome-wide alterations in DNA methylation","volume":"22","author":"Duncan","year":"2012","journal-title":"Genome Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.celrep.2014.10.063","article-title":"Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation","volume":"9","author":"Wu","year":"2014","journal-title":"Cell Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jnci\/djq497","article-title":"DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma","volume":"103","author":"Christensen","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/neuonc\/nox183","article-title":"Glioma CpG island methylator phenotype (G-CIMP): Biological and clinical implications","volume":"20","author":"Malta","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature04433","article-title":"Histone demethylation by a family of JmjC domain-containing proteins","volume":"439","author":"Tsukada","year":"2006","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1101\/gad.226753.113","article-title":"Induction of sarcomas by mutant IDH2","volume":"27","author":"Lu","year":"2013","journal-title":"Genes Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/NEN.0b013e3182898113","article-title":"Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas","volume":"72","author":"Venneti","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"R608","DOI":"10.1152\/ajpregu.00538.2003","article-title":"HIFs and tumors\u2014Causes and consequences","volume":"286","author":"Ogunshola","year":"2004","journal-title":"Am. J. Physiol.-Regul. Integr. Comp. Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature05915","article-title":"The complex language of chromatin regulation during transcription","volume":"447","author":"Berger","year":"2007","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-resolution profiling of histone methylations in the human genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc2876","article-title":"Covalent histone modifications\u2014Miswritten, misinterpreted and mis-erased in human cancers","volume":"10","author":"Chi","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nchembio.687","article-title":"N 6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO","volume":"7","author":"Jia","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.molcel.2020.12.026","article-title":"R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO\/m6A\/PFKP\/LDHB axis","volume":"81","author":"Qing","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1677\/erc.1.01290","article-title":"Role of hypoxia-inducible factor-1\u03b1 as a cancer therapy target","volume":"13","author":"Patiar","year":"2006","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","article-title":"HIF-1 and tumor progression: Pathophysiology and therapeutics","volume":"8","author":"Semenza","year":"2002","journal-title":"Trends Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/28867","article-title":"Role of HIF-1\u03b1 in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis","volume":"394","author":"Carmeliet","year":"1998","journal-title":"Nature"},{"key":"ref_85","first-page":"22073","article-title":"Clinical and prognostic significance of HIF-1\u03b1 in glioma patients: A meta-analysis","volume":"8","author":"Liu","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_86","first-page":"198","article-title":"Environmental cues like hypoxia can trigger gene expression and cancer development","volume":"1","author":"Shaw","year":"2008","journal-title":"Nat. Educ."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1\u03b1","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2016.09.015","article-title":"Mitochondrial protein lipoylation and the 2-oxoglutarate dehydrogenase complex controls HIF1\u03b1 stability in aerobic conditions","volume":"24","author":"Burr","year":"2016","journal-title":"Cell Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-019-03156-5","article-title":"Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours","volume":"143","author":"Sun","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.imlet.2018.01.015","article-title":"The role of mTOR-mediated signaling in the regulation of cellular migration","volume":"196","author":"Holroyd","year":"2018","journal-title":"Immunol. Lett."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9230479","DOI":"10.1155\/2018\/9230479","article-title":"Targeting mTOR in glioblastoma: Rationale and preclinical\/clinical evidence","volume":"2018","author":"Mecca","year":"2018","journal-title":"Dis. Markers"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/neuonc\/noq052","article-title":"mTOR signaling in glioblastoma: Lessons learned from bench to bedside","volume":"12","author":"Akhavan","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2174\/1381612826666200131100630","article-title":"Wnt\/beta-catenin and PI3K\/Akt\/mtor Signaling Pathways in Glioblastoma: Two main targets for drug design: A Review","volume":"26","author":"Shahcheraghi","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"12700","DOI":"10.1038\/ncomms12700","article-title":"The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway","volume":"7","author":"Carbonneau","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cne.23668","article-title":"DEP domain-containing mTOR-interacting protein in the rat brain: Distribution of expression and potential implication","volume":"523","author":"Caron","year":"2015","journal-title":"J. Comp. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","article-title":"DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival","volume":"137","author":"Peterson","year":"2009","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1152\/physrev.00064.2017","article-title":"DEPTOR at the Nexus of Cancer, Metabolism, and Immunity","volume":"98","author":"Caron","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Liu, Y., Lu, Y., Li, A., Celiku, O., Han, S., Qian, M., and Yang, C. (2020). Mtorc2\/rac1 pathway predisposes cancer aggressiveness in idh1-mutated glioma. Cancers, 12.","DOI":"10.3390\/cancers12040787"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00018-009-8740-3","article-title":"DNA repair in mammalian cells","volume":"66","author":"Pardo","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1349-7006.2011.02134.x","article-title":"IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma","volume":"103","author":"Qi","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","journal-title":"Neurology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/neuonc\/nos261","article-title":"Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation","volume":"15","author":"Li","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ccell.2016.05.018","article-title":"Mutant IDH1 downregulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2","volume":"30","author":"Inoue","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10014-020-00360-4","article-title":"Correlation between IDH, ATRX, and TERT promoter mutations in glioma","volume":"37","author":"Ohba","year":"2020","journal-title":"Brain Tumor Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1158\/0008-5472.CAN-14-0924","article-title":"Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance","volume":"74","author":"Ohba","year":"2014","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1096\/fj.201800547R","article-title":"IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity","volume":"32","author":"Khurshed","year":"2018","journal-title":"FASEB J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eaal2463","DOI":"10.1126\/scitranslmed.aal2463","article-title":"2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity","volume":"9","author":"Sulkowski","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ccell.2015.11.006","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1158\/0008-5472.CAN-16-2263","article-title":"The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion\u2013mediated cytotoxicity","volume":"77","author":"Tateishi","year":"2017","journal-title":"Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/neuonc\/nos301","article-title":"The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells","volume":"15","author":"Johannessen","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1021\/acs.chemrestox.7b00009","article-title":"Oncometabolites d-and l-2-hydroxyglutarate inhibit the AlkB family DNA repair enzymes under physiological conditions","volume":"30","author":"Chen","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.celrep.2015.11.029","article-title":"Oncometabolite D-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents","volume":"13","author":"Wang","year":"2015","journal-title":"Cell Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaaq1427","DOI":"10.1126\/scitranslmed.aaq1427","article-title":"IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response","volume":"11","author":"Mendez","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1535-7163.MCT-19-0103","article-title":"Blockade of glutathione metabolism in IDH1-mutated glioma","volume":"19","author":"Tang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.15252\/emmm.201707729","article-title":"Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways","volume":"9","author":"Fack","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0076-6879(81)77046-0","article-title":"[44] Glutathione peroxidase","volume":"Volume 77","author":"Wendel","year":"1981","journal-title":"Methods in Enzymology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00401-013-1194-6","article-title":"Autophagy and oxidative stress in gliomas with IDH1 mutations","volume":"127","author":"Gilbert","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s13277-014-2644-z","article-title":"Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation","volume":"36","author":"Shi","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9964","DOI":"10.1073\/pnas.1913633117","article-title":"Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism","volume":"117","author":"Yu","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","first-page":"875","article-title":"Targeting Nrf2 driven glutathione de novo synthesis as a novel strategy to suppresses IDH1-mutated glioma","volume":"79","author":"Liu","year":"2019","journal-title":"Mol. Cell. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Biedermann, J., Preussler, M., Conde, M., Peitzsch, M., Richter, S., Wiedemuth, R., Abou-El-Ardat, K., Kr\u00fcger, A., Meinhardt, M., and Schackert, G. (2019). Mutant IDH1 differently affects redox state and metabolism in glial cells of normal and tumor origin. Cancers, 11.","DOI":"10.3390\/cancers11122028"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/glia.21113","article-title":"Glutamate and the biology of gliomas","volume":"59","author":"Sontheimer","year":"2011","journal-title":"Glia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1007\/s11064-008-9758-x","article-title":"Astrocyte and neuron intone through glutamate","volume":"33","author":"Yang","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1007\/s00018-013-1274-8","article-title":"Regulation and dysregulation of astrocyte activation and implications in tumor formation","volume":"70","author":"Yang","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jphs.08R01CR","article-title":"Regulation of neuronal glutathione synthesis","volume":"108","author":"Aoyama","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/his.14014","article-title":"The role of glutaminase in cancer","volume":"76","author":"Masisi","year":"2020","journal-title":"Histopathology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1073\/pnas.1002459107","article-title":"Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species","volume":"107","author":"Suzuki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"16040","DOI":"10.1038\/ncomms16040","article-title":"BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases","volume":"8","author":"Papathanassiu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cell.2018.08.038","article-title":"Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma","volume":"175","author":"McBrayer","year":"2018","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/JBM.S70716","article-title":"IDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives","volume":"7","author":"Mondesir","year":"2016","journal-title":"J. Blood Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Lemieux","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1200\/JCO.19.03327","article-title":"Ivosidenib in isocitrate dehydrogenase 1\u2013mutated advanced glioma","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"Chin. Ger. J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/leu.2017.46","article-title":"Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Leukemia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00401-017-1677-y","article-title":"Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo","volume":"133","author":"Pusch","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2019.37.15_suppl.2004","article-title":"Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas","volume":"37","author":"Natsume","year":"2019","journal-title":"Chin. Ger. J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): A first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1016\/j.bbrc.2018.08.068","article-title":"Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2","volume":"503","author":"Ma","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"TPS2574","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS2574","article-title":"INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1\/2 (IDH1\/2) mutation","volume":"38","author":"Mellinghoff","year":"2020","journal-title":"Chin. Ger. J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-10-533604","article-title":"IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition","volume":"125","author":"Kernytsky","year":"2015","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"13853","DOI":"10.1038\/s41598-017-14065-w","article-title":"A brain penetrant mutant IDH1 inhibitor provides in vivo survival benefit","volume":"7","author":"Kopinja","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_147","first-page":"7009","article-title":"A phase 1 dose escalation study of the IDH1 m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"36","author":"Watts","year":"2018","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acsmedchemlett.7b00342","article-title":"Discovery and evaluation of clinical candidate IDH305, a brain penetrant mutant IDH1 inhibitor","volume":"8","author":"Cho","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1182\/blood.V128.22.1073.1073","article-title":"A phase I study of IDH305 in patients with advanced malignancies including relapsed\/refractory AML and MDS that harbor IDH1R132 mutations","volume":"128","author":"DiNardo","year":"2016","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/BLCTT.S177913","article-title":"IDH1-mutated relapsed or refractory AML: Current challenges and future prospects","volume":"9","author":"Montesinos","year":"2019","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH Inhibitors in AML\u2014Promise and Pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.clml.2016.04.006","article-title":"Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120","volume":"16","author":"Birendra","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: Analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/blood-2018-99-117426","article-title":"Incidence of differentiation syndrome with ivosidenib (IVO) and enasidenib (ENA) for treatment of patients with relapsed or refractory (R\/R) isocitrate dehydrogenase (IDH) 1-or IDH2-mutated acute myeloid leukemia (AML): A systematic analysis by the US Food and Drug Administration (FDA)","volume":"132","author":"Norsworthy","year":"2018","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11060-019-03359-w","article-title":"Extracellular glutamate and IDH1 R132H inhibitor promote glioma growth by boosting redox potential","volume":"146","author":"Tiburcio","year":"2020","journal-title":"J. Neuro-Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/carcin\/bgz134","article-title":"Friend or foe\u2014IDH1 mutations in glioma 10 years on","volume":"40","author":"Huang","year":"2019","journal-title":"Carcinogenesis"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2345\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:58:24Z","timestamp":1760165904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/9\/2345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":157,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cells10092345"],"URL":"https:\/\/doi.org\/10.3390\/cells10092345","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]}}}